Practical Updates in Adult-onset Mastocytosis, MCAS, and HAT for the Dermatologist

Dr. Mariana Castells, a noted expert in mastocytosis, presented an extensive lecture on mast cell activation syndromes (MCAS) and hereditary alpha tryptasemia (HAT), emphasizing their clinical implications for dermatologists. She began by highlighting the necessity for differential diagnoses in MCAS, illustrated through a case study of a young woman suffering from chronic symptoms often misattributed to other conditions. Dr. Castells discussed the variety of mast cells in the human body, their mediators (like histamine and prostaglandins), and how these can lead to diverse symptoms across different organ systems. She outlined the classification of mast cell disorders into primary and secondary categories based on clonal expansion or activation due to underlying diseases. Dr. Castells introduced hereditary alpha tryptasemia, a genetic condition impacting a significant portion of the population, which can lead to severe allergic reactions. She stressed the importance of personalized treatment plans that address triggers specific to individual patients and the recent development of targeted therapies, such as the FDA-approved drug avapritinib for systemic mastocytosis. The lecture concluded with an overview of the multidisciplinary approach taken at the Brigham and Women’s Mastocytosis Center focused on both treatment and research into mast cell disorders. Overall, the presentation underscored the complexity of mast cell pathophysiology and the evolving understanding of these conditions within the field of dermatology.